A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

Back to Search
Print
Bookmark Trial

NCT00068042

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Los Angeles, California, 90048, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of acromegaly

- IGF-I levels >=1.3xULN (upper limit of normal) at screening

- No history of radiotherapy or prior treatment with other drugs for acromegaly

- Minimum of two months must have elapsed post surgery prior to screening

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or
IGF-I concentrations


- AST/ALT >= 3xULN (upper limit of normal)


- Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI


- Visual field defects (except post surgical stable residual defects)


- Unable to self administer drug

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

AcromegalyCanadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437
  1. Edmonton, Alberta
  2. Edmonton, Alberta
  3. Halifax, Nova Scotia
  4. Toronto, Ontario
  5. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
AcromegalyLong Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
NCT00658879
ALL GENDERS
0+
years
MULTIPLE SITES
AcromegalyLong Term Study With B2036-PEG
NCT00143416
  1. Kobe City, Hyogo Pref
  2. Kozukue-cho, Kouhoku-ku, Yokohama-shi, Kanagawa
  3. Hamamatsu-shi, Shizuoka-ken
  4. Bonkyo-ku, Tokyo
  5. Shinjuku-ku, Tokyo
  6. Gakuhara, Kishiwada, Osaka,
  7. Kyoto,
  8. Sannomaru-cho, Naka-ku, Nagoya-shi,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
AcromegalyPegvisomant And Sandostatin LAR Combination Study
NCT00068029
  1. Los Angeles, California
  2. Boston, Massachusetts
  3. Chapel Hill, North Carolina
  4. Charlottesville, Virginia
  5. Darlinghurst, New South Wales
  6. Fitzroy, Victoria
  7. Fizroy, Victoria
  8. Rio de Janeiro, RJ
  9. São Paulo, SP
  10. Halifax, Nova Scotia
  11. Halifax, Nova Scotia
  12. Toronto, Ontario
  13. Montpellier Cedex,
  14. Nice Cedex,
  15. Berlin,
  16. Dresden,
  17. Hannover,
  18. Genova,
  19. Messina,
  20. Milano,
  21. Torino,
  22. Mexico, DF
  23. Col La Raza, Mexico Df
  24. Nijmegen,
  25. Oslo,
  26. Hospitalet de Llobregat, Barcelona
  27. Madrid,
  28. Belfast, Antrim
  29. Leeds,
  30. London,
  31. London,
  32. Manchester,
  33. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Official Title  ICMJE A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Brief Summary The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acromegaly
Intervention  ICMJE
  • Drug: Pegvisomant
  • Drug: Sandostatin LAR
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 30, 2005)		100
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE May 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of acromegaly
  • IGF-I levels >=1.3xULN (upper limit of normal) at screening
  • No history of radiotherapy or prior treatment with other drugs for acromegaly
  • Minimum of two months must have elapsed post surgery prior to screening

Exclusion Criteria:

  • Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations
  • AST/ALT >= 3xULN (upper limit of normal)
  • Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI
  • Visual field defects (except post surgical stable residual defects)
  • Unable to self administer drug
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Brazil,   Canada,   France,   Germany,   Greece,   Ireland,   Italy,   Norway,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00068042
Other Study ID Numbers  ICMJE PEGA-0435-003
A6291004
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP